• Hansoh Pharma reported a pivotal Phase 3 trial success for HS-10374 in adults with moderate-to-severe plaque psoriasis.
• The study showed clear clinical improvement versus placebo, supporting a favorable benefit-risk profile consistent with the TYK2 class.
• Detailed results have not been presented yet; the company plans to disclose the data at a future dermatology congress.
• Regulatory discussions in China are set to start to support New Drug Application preparations, signaling a potential late-stage pipeline catalyst.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 21, 2026, and is solely responsible for the information contained therein.